Muscle Protein Miro1 Emerges as Hidden Driver of Insulin Resistance in Type 2 Diabetes

In the skeletal muscle of people with Type 2 diabetes, researchers have found a protein present at higher levels than it should be, and they now think it may be one of the hidden drivers of the disease. The protein is called Miro1. The findings, published in Nature Communications, bear on insulin resistance, which is a central feature of Type 2 diabetes.

Miro1, short for Mitochondrial Rho GTPase1, sits on the outer membrane of mitochondria, the small structures inside cells that produce energy. The researchers believe that too much of it interferes with how muscle responds to insulin, which makes it harder for the body to regulate blood sugar.

To test that idea, the team followed Miro1 through three settings: laboratory cells, preclinical models, and people living with Type 2 diabetes. Across them, the buildup of Miro1 impaired the muscle's response to insulin. When the scientists removed the protein in the preclinical models, insulin responsiveness returned. That result is the strongest evidence in the study that Miro1 contributes directly to the problem rather than simply appearing alongside it.

The researchers then asked whether exercise changes Miro1 levels in people. They ran a randomized controlled trial in participants with obesity and Type 2 diabetes, comparing aerobic exercise with standard medical care. Those assigned to exercise showed a decline in muscle Miro1. The drop came alongside improvements in insulin sensitivity and in the muscles' capacity to produce energy. The findings suggest that lowering Miro1 may be one way exercise helps the body respond better to insulin.

Dr. John P. Kirwan, the study's senior author, described the work as the product of years of effort. "Insulin resistance in muscle is at the heart of Type 2 diabetes, and its molecular causes have remained frustratingly unclear," he said, adding that the study identifies Miro1 as a key part of the answer. He called it a new therapeutic target for the field, and for patients a deeper explanation of why exercise works so well and a path toward treatments that could one day complement it.

Kirwan recently became executive director of the OU Health Harold Hamm Diabetes Center at the University of Oklahoma, where he is also Vice Provost for Diabetes Programs and holds the Chickasaw Nation Endowed Chair in Diabetes Research. He did the work while at LSU's Pennington Biomedical Research Center. The first author, Elizabeth Heintz, is a doctoral candidate who worked in Pennington's Integrated Physiology and Molecular Medicine Laboratory. Co-corresponding author Christopher Axelrod has also moved to the Hamm center to continue the research with Kirwan. Dr. Jennifer Rood, Pennington's Interim Senior Vice Chancellor and Executive Director, said the study shows the value of linking basic science, clinical studies and population-based research.

The limits are plain. The restoration of insulin responsiveness was shown in preclinical models, while the human trial showed that exercise lowered Miro1 alongside better insulin sensitivity. Whether directly targeting Miro1 can yield safe and effective treatments for people remains to be established. Kirwan plans to pursue that question at the Hamm center, combining laboratory experiments with studies in people. "Ultimately, we are looking for cures," he said, "and we hope these recent findings could be part of the solution." Funding came from five National Institutes of Health institutes: diabetes and digestive and kidney diseases, aging, complementary and integrative health, heart, lung, and blood, and general medical sciences.